You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Aminoglycosides with reduced ototoxicity via miRNA targeting
SBC: NUBAD LLC Topic: NIAIDPROJECT SUMMARYAminoglycosides are one of the cheapest and well-known antibiotics in clinical use for over 70 years, but one of the major limitations in their use is their ototoxicity. We are developing fast and low cost methods to develop aminoglycosides with anti- ribosomal activities and reduced toxicity. In this project, we will identify novel aminoglycoside antibacterials, that show reduced o ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Nitric Oxide Microfluidic Sensor
SBC: CLINICAL SENSORS, INC. Topic: NIAIDDESCRIPTION provided by applicant This Small Business Innovation Research SBIR Phase I project aims to develop a microfluidic based nitric oxide NO sensor as an early sepsis risk assessment device Sepsis causes significant strain on the U S healthcare system consuming over $ billion annually due to extended hospital stays and significant morbidity and mortality Rapid diagnosis and in ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
RNA Detection as an Improved Diagnostic Assay for Human Leptospirosis
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDDESCRIPTION provided by applicant Leptospirosis a zoonotic disease is an important public health problem worldwide It is caused by spirochete bacteria belonging to nine species and more than serovars of the genus Leptospira In the US there is increasing awareness of the importance of leptospirosis as the cause of disease among inner city populations military personnel and individuals ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
IRE1beta Inhibitors: Novel Therapeutics to Manage Excess Mucus in Asthma
SBC: Irex Pharma LLC Topic: NIAIDPROJECT SUMMARY Over 25 million Americans have asthma, which places an economic burden on the U.S. of $81.9 billion. Airway mucus overproduction is a hallmark of asthma, and the quantity and tenacity of mucus are increased during airway exacerbations. Mucolytics degrade mucus, but do not reduce its production. Although corticosteroids and other anti-inflammatory therapies indirectly decrease mucus ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDDESCRIPTION provided by applicant This proposal seeks to develop a novel vaccine against Lyme disease by targeting Ixodes scapularis proteins critical for Borrelia burgdorferi transmission from the tick to mammalian host Earlier work has identified four tick proteins Salp TRE tHRF and TSLPI that facilitate different steps of spirochete transmission and immunity against these protein ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Targets of Acquired Tick-Resistance As Anti-Tick Vaccines
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDABSTRACTThis proposal seeks to develop a novel vaccine against pathogens transmitted by the blacklegged tick, Ixodes scapularis, by targeting tick salivary proteins (Salps) critical for tick feeding. I. scapularis Salps provide functions critical for evading host defense responses detrimental to the tick. Further, these salivary functions are also co-opted by tick-transmitted pathogens to ensure t ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of Peptide Antibiotic Nucleic Acids
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDPROJECT SUMMARYZika virus, an emerging flavivirus, is associated with severe clinical outcomes, including Guillain-Barré syndrome and birth defects. Transmission of Zika virus is primarily mosquito- borne. Mosquito salivary proteins are known to enhance infectivity and pathogenesis in Zika, dengue and West Nile viruses by modulating immune responses. This proposal seeks to develop a novel vaccine ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Targeting STT3A and STT3B to Block Flavivirus Replication
SBC: New England Discovery Partners, LLC Topic: NIAIDAbstractMosquito borne flaviviruses cause disease worldwidewith members such as dengue virusDENVZika virusZIKVand west nile virusWNVinfecting more thanmillion individuals annuallyThe availability of small molecule antivirals that reduce flavivirus infection therefore could have an immediate and substantial impact on public health programs that seek to improve outcomes for populations infected with ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Immunization with mosquito AgTRIO protein to prevent malaria
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDPROJECT SUMMARYMalaria is one of the world’s major public health threats. The disease is transmitted when an infected female Anopheles mosquito, while probing for a blood meal, injects saliva together with Plasmodium sporozoites into the skin of the vertebrate host (1, 2). To date, a highly effective, safe and FDA-approved human vaccine against malaria has not been developed. The most establishe ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health